Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Jonathan Lindner, MD, offers an update on the use of echocardiography and bubble contrast agents in a therapy role to help revascularize STEMI patients and increase drug and gene delivery.
Cardiologists and other physicians have always believed cardiac transthyretin amyloidosis, a progressive heart condition associated with a high mortality rate, was irreversible. Now, though, new evidence suggests that there may be hope.
Cedars-Sinai researchers are developing a deep-learning algorithm to personalize patient cardiac risk predictions in a patient-friendly, graphical report.
Findings from the SOLVE-CRT study were presented to attendees at Heart Rhythm 2023. "Our results showed the study was safe, effective and feasible," Singh said.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
